SELLEST PODCASTIST 🔗
ESMO 2014
Keskmine heli pikkus:
6 minutes
Inglise
Ameerika Ühendriigid
28 jagu
alates 11. veebruar 2015
episodic
VIIMANE OSA 🔗
Dr Symonds (University Hospital of Leicester, Leicester, UK) talks to ecancertv at ESMO 2014 about his work looking at the use of experimental, drug cediranib, in the treatment of cervical cancer.
OTSI VARASEMAID OSASID
Otsi kanali ESMO 2014 viimaseid osasid.
EELMISED OSAD 🔗
ecancer's Gordon McVie talks to Anastassia Negrouk, of the European Organisation for Research and Treatment of Cancer (EORTC), at ESMO 2014 on managing data in clinical trials and encouraging more personalised medicine to take place for the progression of cancer care.
Prof Lefebvre (Northern France Comprehensive Cancer Centre, Lille, France) talks to ecancertv at ESMO 2014 about the Make Sense campaign, and the ways in which they are raising the public's awareness of head and neck cancer.
Dr Swain (Washington Cancer Institute, Washington, USA) talks to ecancertv at ESMO 2014 about the results of the CLEOPATRA trial, which demonstrated significant survival benefits for patients with HER2 breast cancer when treated with a combination of pertuzumab, trastuzumab and chemotherapy.
Prof Meunier, Director General of the European Organisation for Research and Treatment of Cancer, Belgium (EORTC) talks to ecancertv at ESMO 2014 about the financial impacts of cancer and the quality of life issues associated with them.
Dr Tahara (National Cancer Center Hospital East, Kashiwa, Japan) talks to ecancertv at ESMO 2014 about the development of a new targeted therapy for the treatment of iodine-refractory thyroid cancer.
Dr Minig (Valencia Institute of Oncology, Valencia, Spain) talks to ecancertv at ESMO 2014 about the need to establish a more standardised world-wide protocol for the treatment of advanced stage ovarian cancer with a focus on a multidisciplinary and specialised approach to surgery which would impro…
Dr Jean-Pascal Machiels of Cliniques Universitaires Saint-Luc, Brussels, Belgium talks to ecancertv at ESMO 2014 in Madrid Spain. He presents results from a phase III trial on the tyrosine kinase inhibitor, afatinib and the significant improvements it has shown in progression-free survival for pati…
Dr Weber (Moffitt Cancer Center, Tampa, USA) talks to ecancertv at ESMO 2014 about the results of a phase III trial which indicated that monoclonal antibody, nivolumab, achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progr…
Dr Gligorov (Assistance Publique Hôpitaux de Paris, Paris, France) talks to ecancertv at ESMO 2014 about his open-label randomised phase III IMELDA trial on metastatic breast cancer.
He studied whether the addition of capecitabine to maintenance bevacizumab - continued until disease progression af…
Vastutamatussäte: Sellele lehele manustatud taskuhäälingusaade ja kunstiteosed pärinevad ecancer-lt, mis on selle omaniku omand ja ei ole seotud ettevõttega Listen Notes, Inc.
PODCASTIDE OTSINGUMOOTOR
Saate kasutada meie veebisaiti3,836,261taskuhäälingusaadete ja197,563,833osade otsimiseks inimeste, kohtade või teemade järgi.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
OTSI VARASEMAID OSASID
Otsi kanali ESMO 2014 viimaseid osasid.
VALI SEE PODCAST
Why to claim podcasts?
If you are a podcaster, the best way to manage your podcasts on Listen Notes is by claiming your Listen Notes
podcast pages.
It is a great, free way to engage the podcast community and increase the visibility of your podcasts.
After claiming your Listen Notes podcast pages, you will be able to:
✓
Manually refresh the RSS feed to sync up
✓
Get a verified badge (
✓
) alongside with your podcast name on Listen Notes
✓
Post kuulutused for sponsorship,
guests, co-hosts,
cross-promotion...
✓
Respond to listener comments on Listen Notes
✓
Use speech-to-text techniques to transcribe your show and
edit transcripts
✓
Improve the presence of your podcasts, e.g., self-service
taskuhäälingu tegija intervjuu...
✓
If you share your Listen Notes page and at-mention @ListenNotes
on X (formerly Twitter),
meie ametlik X-i konto (endine Twitter) will retweet to promote
your show to our followers.
Coming soon:
◯ Self-service promotion on Listen Notes
◯ Track your podcast stats on Listen
Notes, e.g., listens, page
views...
◯ Manage episodes
MUUDA
Aitäh, et aitad hoida podcastide andmebaasi ajakohasena.